InSite Vision, the Alameda, CA-based developer of drugs for eye diseases, said today it has joined pharma giant Merck in bringing a patent infringement lawsuit against Sandoz, a generic drugmaker. Sandoz has recently filed an abbreviated new drug application with the FDA for clearance to start marketing a generic version of azithromycin (Azacite) for the treatment of eye infections. Merck will the take the lead in the patent litigation, Insite said.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
